Establishment and Characterization of a CD20-Positive NK/T-Cell Lymphoma Cell Line

• Published in: Clinical laboratory (Heidelberg) Vol. 61; no. 7; p. 731
• Main Authors: Gu, Linhui, Hong, Lianlian, Ling, Zhiqiang, Feng, Jianguo, Zheng, Zhiguo, Du, Lingbin, Mou, Hanzhou, Sun, Wenyong, Kong, Xiangming, Ling, Yutian, Jiang, Zhiming, Zhu, Chihong, Mao, Weimin, Qian, Lijuan
• Format: Journal Article
• Language: English
• Published: Germany 2015
• Subjects: Antigens, CD20 - metabolism; Biomarkers, Tumor - genetics; Biomarkers, Tumor - metabolism; Cell Line, Tumor; Cell Shape; Chromosome Aberrations; Comparative Genomic Hybridization; Flow Cytometry; Gene Rearrangement; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Genes, Immunoglobulin Heavy Chain; Genes, T-Cell Receptor gamma; Genetic Predisposition to Disease; Herpesvirus 4, Human - genetics; Humans; Immunohistochemistry; Immunomagnetic Separation; Immunophenotyping - methods; Karyotyping; Lymphoma, Extranodal NK-T-Cell - genetics; Lymphoma, Extranodal NK-T-Cell - immunology; Lymphoma, Extranodal NK-T-Cell - metabolism; Lymphoma, Extranodal NK-T-Cell - pathology; Lymphoma, Extranodal NK-T-Cell - virology; Male; Nose Neoplasms - genetics; Nose Neoplasms - immunology; Nose Neoplasms - metabolism; Nose Neoplasms - pathology; Nose Neoplasms - virology; Phenotype; Real-Time Polymerase Chain Reaction; Young Adult
• ISSN: 1433-6510
• DOI: 10.7754/Clin.Lab.2014.140602

CD20 positive NK/T-cell lymphoma is extremely rare and difficult for clinical treatment. Due to the lack of an established cell model for this disease, less is known about its biological characterization and potential therapeutic options. A cell line of NK/T-cell lymphoma, which was enriched by magnetic sorting with proper cell surface markers (CD56) from peripheral blood mononuclear cells (PBMCs) drawn from a 21-year-old male patient with nasal angiocentric NK/T-cell lymphoma, was designated as ZQNK-29. Immunophenotypic analysis of ZQNK-29 was performed by flow cytometric and immunohistochemical analysis. Comparative genomic hybridization (CGH) analysis was used for cytogenetic analysis of ZQNK-29. Potential rearrangements of the immunoglobulin gene and Epstein-Barr virus (EBV) infection were examined by PCR and RT-PCR, respectively. ZQNK-29 cells express the phenotypic T-cell marker (CD3), T cell activation markers (HLA-DR), markers for both NK and cytotoxic T lymphocytes (TIA-1), and B-lineage marker CD20; however, expression of CD56 was not detected in expanded ZQNK-29 cells although this NK cell surface marker was used as one of selective cell surface markers for the initial isolation of NK/T cells. RT-PCR analysis showed that the pattern of gene expressions for infected EBV was latency type III, with the expressions of LMP1, EBNA-1, and EBNA-2; no rearrangements were found in the heavy-chain of the immunoglobulin gene or in the y chain of the T cell receptors (TCRs) gene. CGH analysis demonstrated that ZQNK-29 possessed an abnormal karyotype, 46XY, 1p (dist)+, 4p (dist)+, 4q (mid)-, 5q (mid)-, 9q (dist)+, 16p (dist)+, 16q (dist)+, 17p+, 17q (dist)+, 19q (dist)+, 20p+, 20q+, 21q+, and 22q+. Of these, 1p (dist)+, which has been confirmed to be mitochondrial DNA amplification, is believed to be mainly caused by EBV infection. ZQNK-29 is a well characterized premature human NK/T-cell lymphoma cell line with expression of the B-cell marker CD20 and will provide a useful pre-clinic model for characterization and potential therapeutic studies of the aggressive NK/T-cell lymphoma.